Thus, further investigation of the expression levels of NSD1, NSD2, and NSD3 is warranted, as these could serve as rapidly exploitable prognostic biomarkers in HPV+ HNSCC, providing a metric for appropriate treatment de-intensification. The gene discussed is NSD3; the disease is head and neck squamous cell carcinoma.